LIBRETTO-531
LIBRETTO-531: Phase III Trial of Selpercatinib vs Cabozantinib or Vandetanib in Patients With Advanced RET-Mutant Medullary Thyroid Cancer

Released: October 25, 2023

Activity

Progress
1
Course Completed